Lipodystrophy Pharmaceutical and Healthcare Pipeline Review H2


Wise.Guy12

Wise.Guy.

Lipodystrophy Treatment Pipeline Review H2 2016

PUNE, INDIA, December 14, 2016 /EINPresswire.com/ — GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/649790-lipodystrophy-pipeline-review-h2-2016

The report provides comprehensive information on the therapeutics under development for Lipodystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lipodystrophy and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
– The report provides a snapshot of the global therapeutic landscape of Lipodystrophy
– The report reviews pipeline therapeutics for Lipodystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Lipodystrophy therapeutics and enlists all their major and minor projects
– The report assesses Lipodystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Lipodystrophy

Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Lipodystrophy
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Lipodystrophy pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Content
Lipodystrophy Overview 6
Therapeutics Development 7
Pipeline Products for Lipodystrophy – Overview 7
Lipodystrophy – Therapeutics under Development by Companies 8
Lipodystrophy – Pipeline Products Glance 9
Late Stage Products 9
Early Stage Products 10
Lipodystrophy – Products under Development by Companies 11
Lipodystrophy – Companies Involved in Therapeutics Development 12
Aegerion Pharmaceuticals, Inc. 12
Akcea Therapeutics Inc 13
Ambrx, Inc. 14
Amunix Operating Inc. 15
Bolder Biotechnology, Inc. 16
Lipodystrophy – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 23
Drug Profiles 25
AMX-342 – Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
ARX-328 – Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
BBT-031 – Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
metreleptin – Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
volanesorsen sodium – Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Continued…

ACCESS REPORT @ https://www.wiseguyreports.com/reports/649790-lipodystrophy-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Continuous Positive Airway Pressure (CPAP) Devices Market Analysis and Forecast to 2027

Global Continuous Positive Airway Pressure (CPAP) Devices Market Information by product, type and by CPAP machines – forecast to 2027

Key Players: Resumed (Asia), Philips Healthcare (US), Fisher & Paychex (NZ), 3B Medical (US), Apex Medical (Taiwan).

— Market Research Future

PUNE, MAHARASHTRA , INDIA , December 14, 2016 /EINPresswire.com/ — Market Scenario:
Continuous positive airway pressure therapy is most widely recognized treatment for obstructive Sleep Apnea that utilizes continuous mild air pressure. These devices are utilized to keep the airways open during sleep and furthermore to control the yield pressure keeping the airflow pressure constant. The global continuous positive airway pressure devices market is relied with steady growth, posting a CAGR of nearly XX% during the forecast period.

Key Players of Continuous Positive Airway Pressure (CPAP) Devices Market:
• Resumed (Asia)
• Philips Healthcare (US)
• Fisher & Paychex (NZ)
• 3B Medical (US)
• Apex Medical (Taiwan)
• Apria Healthcare (US)
• Armstrong Medical (UK)
• BMC Medical (China)
• Cardinal Health (US)
• Curative Medical (US)

Request a Sample Copy @ https://www.marketresearchfuture.com/sample-request/global-continuous-positive-airway-pressure-cpap-forecast-to-2027

Segments:
Global Continuous Positive Airway Pressure (CPAP) device market has been segmented on the basis of product type which includes CPAP motors, CPAP hoses, CPAP mask). On the basis CPAP machines which consists CPAP nasal machine, Bopp Bi-level machine.

Study Objectives of Continuous Positive Airway Pressure (CPAP) Devices Market:
• To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the Global Continuous Positive Airway Pressure(CPAP) devices Market.
• To provide insights about factors affecting the market growth.
• To Analyze the Global Continuous Positive Airway Pressure (CPAP) devices Market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
• To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and Row.
• To provide country level analysis of the market with respect to the current market size and future prospective.
• To provide country level analysis of the market for segments by product type, by CPAP machines and sub-segments.
• To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.
• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Continuous Positive Airway Pressure(CPAP) devices Market.

Browse full report @ https://www.marketresearchfuture.com/reports/global-continuous-positive-airway-pressure-cpap-forecast-to-2027

Regional Analysis of Continuous Positive Airway Pressure (CPAP) Devices Market:
Globally North America is the largest market for Continuous Positive Airway Pressure (CPAP) device market, large share of this market is focused on the high prevalence of sleep disorders in people around the world. The North American market for Continuous Positive Airway Pressure (CPAP) device is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. Europe is the second-largest market for Continuous Positive Airway Pressure (CPAP) device, which is expected to grow at a CAGR of XX%.

Related Report:
Global Ovarian Cysts Market Information, by type (functional cysts, polycystic ovary syndrome, dermoid cysts, endometriomas and others), by treatment (polycystic ovary syndrome (PCOS) drugs, laparoscopy, laparotomy and others), by end user (hospital, clinics and others) – Forecast to 2022
Know more about this report @ https://www.marketresearchfuture.com/reports/ovarian-cysts-market-research-report-global-forecast-to-2022

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact:
Akash Anand
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: akash.anand@marketresearchfuture.com

Akash Anand
Market Research Future
+1 646 845 9312
email us here


Source: EIN Presswire

Pruritus Therapeutic and Drug Pipeline Review H2


Wise.Guy12

Wise.Guy.

Pruritus Treatment Pipeline Review H2 2016

PUNE, INDIA, December 14, 2016 /EINPresswire.com/ — GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/822688-pruritus-pipeline-review-h2-2016
‘Pruritus – Pipeline Review, H2 2016’, provides an overview of the Pruritus pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Pruritus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects.
Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
The report provides a snapshot of the global therapeutic landscape of Pruritus
The report reviews pipeline therapeutics for Pruritus by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Pruritus therapeutics and enlists all their major and minor projects
The report assesses Pruritus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Pruritus

Reasons to Buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Pruritus
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Pruritus Overview 10
Therapeutics Development 11
Pipeline Products for Pruritus – Overview 11
Pipeline Products for Pruritus – Comparative Analysis 12
Pruritus – Therapeutics under Development by Companies 13
Pruritus – Therapeutics under Investigation by Universities/Institutes 15
Pruritus – Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Pruritus – Products under Development by Companies 19
Pruritus – Products under Investigation by Universities/Institutes 21
Pruritus – Companies Involved in Therapeutics Development 22
Albireo AB 22
Alveonix AG 23
Amorepacific Corporation 24
Asana BioSciences, LLC 25
Cara Therapeutics, Inc. 26
Chugai Pharmaceutical Co., Ltd. 27
Creabilis SA 28
ELORAC, Inc. 29
Faes Farma, S.A. 30
GlaxoSmithKline Plc 31
Hydra Biosciences, Inc. 32
LEO Pharma A/S 33
Merck & Co., Inc. 34
NeRRe Therapeutics Ltd 35
Nippon Shinyaku Co., Ltd. 36
Patara Pharma, Inc. 37
Phosphagenics Limited 38
RDD Pharma Ltd. 39
Sanwa Kagaku Kenkyusho Co., Ltd. 40
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/822688-pruritus-pipeline-review-h2-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Ophthalmology Market Consumption 2016 Forecast to 2022


Wise.Guy12

Wise.Guy.

Ophthalmology Global Market Segmentation and Therapeutics Analysis 2022

PUNE, INDIA, December 14, 2016 /EINPresswire.com/ — GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/822687-global-ophthalmology-drugs-market-the-forecast-period

Ophthalmology is a therapy area that deals with the diagnosis, treatment and prevention of diseases associated with the eyes and visual system. Most eye disorders occur over a long period of time, and are initially asymptomatic or cause only a slight decrease in vision. However, over time this becomes quite marked. Ophthalmologic disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.
Angiogenesis inhibitors are the most effective and most common therapies used in ophthalmology; this class of compounds has been the most commercially successful in the past decade, with products such as Eylea and Lucentis generating strong annual revenues. Although there are many generics available across the majority of ophthalmology disorders, there are a number of premium products that attract substantial revenues – in particular Eylea, Lucentis, Lumigan and Restasis. The report focuses on five key indications within ophthalmology: glaucoma, age-related macular degeneration (AMD), diabetic macular edema, diabetic retinopathy and dry eye syndrome. There are currently no therapeutic options available for the treatment of dry AMD, increasing the need for extensive R&D within this area.
Although there is a high degree of failure and uncertainty within the R&D of ophthalmology drugs, the number of drugs in the pipeline is very high, at 734. The majority of pipeline products are novel active pharmaceutical ingredients, with only a small proportion of products being either generics or repositioned from other indications. This shows progression in terms of the variety of different molecules being developed as therapeutic agents within the ophthalmology pipeline. The expected growth of the ophthalmology market over the forecast period is attributed to the approval of new drugs, as well as rising prevalence.

Scope
Global revenues for the ophthalmology market are forecast to grow at a compound annual growth rate of 9.48%, from $13.7 billion in 2015 to $26 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
The ophthalmology pipeline is large and diverse, and contains 734 products. How does the composition of the pipeline compare with that of the existing market?
What mechanisms of action and molecule types are most commonly being trialed in pipeline products in the various key indications?
Which products will contribute to market growth most significantly, and which will achieve blockbuster status?
Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?

Reasons to Buy
This report will allow you to:
Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
Visualize the composition of the ophthalmology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
Analyze the ophthalmology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
Understand the growth in patient epidemiology and market revenues for the ophthalmology market, globally and across the key players and product types
Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various ophthalmology disorders
Identify commercial opportunities in the ophthalmology deals landscape by analyzing trends in licensing and co-development deals

Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 9
2.1 Therapy Area Introduction 9
2.1.1 Glaucoma 9
2.1.2 Age-Related Macular Degeneration 9
2.1.3 Diabetic Macular Edema 10
2.1.4 Diabetic Retinopathy 10
2.1.5 Dry Eye Syndrome 10
2.2 Symptoms 11
2.3 Etiology and Pathophysiology 13
2.3.1 Etiology 13
2.3.2 Pathophysiology 15
2.4 Co-morbidities and Complications 18
2.5 Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 19
2.5.1 Glaucoma 19
2.5.2 Age-Related Macular Degeneration 20
2.5.3 Diabetic Macular Edema 22
2.5.4 Diabetic Retinopathy 22
2.5.5 Dry Eye Syndrome 24
2.6 Treatment 26
3 Key Marketed Products 29
3.1 Overview 29
3.2 Lucentis (ranibizumab) 29
3.3 Eylea (aflibercept) 30
3.4 Avastin (bevacizumab) 31
3.5 Restasis (cyclosporine) 32
3.6 Alphagan (brimonidine tartrate) 34
3.7 Lumigan (bimatoprost) 35
3.8 Xalatan (latanoprost 36
4 Pipeline Landscape Assessment 38
4.1 Overview 38
4.2 Pipeline Development Landscape 38
4.3 Mechanisms of Action in the Pipeline 41
4.4 Clinical Trials 43
5 Multi-Scenario Market Forecast to 2022 60
5.1 Overall Market Size 60
5.2 Generic Penetration 61
5.3 Revenue Forecast by Molecular Target 62
…Continued
ACCESS REPORT @ https://www.wiseguyreports.com/reports/822687-global-ophthalmology-drugs-market-the-forecast-period

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Connected Medical Devices Market: Industry Analysis and Global Forecast to 2027

Connected Medical Devices Market information By Product, Care, feature and by End User – Global Forecast to 2027

Key Players: A&D Medical, Aerotel, Animas Corporation, BL Healthcare, Body Media Inc., Boston Scientific, DexCom Inc., Docobo.

— Market Research Future

PUNE, MAHARASHTRA , INDIA , December 14, 2016 /EINPresswire.com/ — Market Segments:
Global Connected Medical Devices Market has been segmented on the basis of products which include Software, BP Monitor, Tracker, ECG, CPAP, Holter, BiPAP, on the basis of feature which includes Communication, Networking, on the basis of Care which consists of Sleep Apnea, Blood Pressure on the basis of end users which includes Hospital, Patient, Clinic.

Key Players of Connected Medical Devices Market:
• A&D Medical
• Aerotel
• Animas Corporation
• BL Healthcare
• Body Media Inc.
• Boston Scientific
• DexCom Inc.
• Docobo
• FitSense Technology

Request a Sample Copy @ https://www.marketresearchfuture.com/sample-request/global-connected-medical-devices-market-research-report-forecast-to-2027

Market Scenario:
Connected medical devices are majorly used for the connected health solutions that replace the traditional healthcare practices. The connected medical devices helps in multiple ways such as the care providers can provide better efficiency and accountability to their customers/ patients, reduction in the cost of treatment and improved quality of treatments. The connected medical device market is expected to grow at a CAGR of XX% at the end of the forecasted period due to technological advancements across the industry, high adoption of smartphones, tablets, and other mobile platforms, applications in the management of chronic diseases, rising point of care, and advantages such as reduced nurses' time and reduced rate of patient readmission.

Study Objectives of Connected Medical Devices Market:
• To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the Global Connected Medical Devices Market.
• To provide insights about factors affecting the market growth.
• To Analyze the Global Connected Medical Devices Market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
• To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia.
• To provide country level analysis of the market with respect to the current market size and future prospective.
• To provide country level analysis of the market for segments by product, by care, by feature, by end user and sub-segments.
• To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.
• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Connected Medical Devices Market.

Browse full report @ https://www.marketresearchfuture.com/reports/global-connected-medical-devices-market-research-report-forecast-to-2027

Brief TOC for Connected Medical Devices:
Introduction
1.1 Definition
1.2 Scope of the study
1.2.1 Research Objectives
1.2.2 Assumptions & Limitations
1.3 Market Structure
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
2.4 Forecast Model
3 Report Excerpt
4 Forecast Indicators
4.1 Introduction
4.2 Growth Drivers
4.2.1 Technological Advancements across the industry
4.2.2 High Adoption of Smartphones, Tablets, and Other Mobile Platforms
4.2.3 Applications in the Management of Chronic Diseases
4.2.4 Rising Point of Care
4.2.5 Advantages such as reduced nurses' time and reduced rate of patient readmission
4.3 Growth Barriers
4.3.1 Data Theft and fraudulent due to lower of Security patient's data
4.3.2 Reluctance towards the usage of these devices over the traditional care methods
4.3.3 Interoperability Issues
4.4 Market Opportunities
4.4.1 Untapped Markets in Emerging Economies
4.4.2 The Shifting Trend Towards Telehealth
4.5 Macroecnomical Indicators
5 Market Analysis
5.1 Porter's Five Force
5.2 Supply Chain Analysis
5.3 Value chain Analysis

Continue…

Regional Analysis of Connected Medical Devices Market:
Globally North America is the largest market for Connected Medical Devices, large share of this market is focused on the rise in new, updated and faster technologies which help in an effective and efficient manner. The North American market for Connected Medical Devices expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. Europe is the second-largest market for Connected Medical Devices, which is expected to grow at a CAGR of XX%.

Related Report:
Global Dental Suture Market Information, by types (absorbable, non-absorbable) by technique (interrupted sutures, continuous sutures, mattress sutures) – Forecast to 2027
Know more about this report @ https://www.marketresearchfuture.com/reports/global-dental-sutures-market-outlook-research-research-report-forecast-to-2027

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact:
Akash Anand
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: akash.anand@marketresearchfuture.com

Akash Anand
Market Research Future
+1 646 845 9312
email us here


Source: EIN Presswire

TieTechnology Now Offers the Best VoIP Phone Systems with it's Suite of Features and Services for Small Businesses

Enterprise Phone Systems

Yealink T48

Polycom VVX 600

Cisco SPA-525G

Call Queing

Companies are switching from landline phones to find the best phone systems for small business to foster growth, while greatly improving customer experience.

Introducing the Best VoIP Phone Systems for Small Business with a Robust Suite of Features, Courtesy of TieTechnology, a Leader in Business Solutions

— Don Anderson

TAMPA, FLORIDA, USA, December 14, 2016 /EINPresswire.com/ — Companies of all sizes and across many industries are switching to voip from traditional landline services to save money and gain a competitive advantage. When businesses compare hosted phone service, it’s clear that the best voip phone systems demonstrably beats out traditional landline systems. The reason is not only lower acquisition and usage costs but also, improved technology.

Companies are switching away from traditional landline telephone services because of the high acquisition, maintenance, and usage costs. This technology, like Cisco VoIP routers and phones, offers high-quality user and data management experience. Traditional telephony relies on outdated technology, known as PBX, or, private branch exchange. This requires bulky and cumbersome equipment and infrastructure, whereas voip is much more convenient. It also offers the following benefits:

Improved User Experience through Better Technology

New and comprehensive voip phone systems for small business reviews clearly show the many faults of traditional landline telephone service. VoIP quality is quite impressive, and everything is managed in the cloud. Companies are benefiting from not having to spend precious capital on equipment setup and maintenance. Business are harnessing the advanced power of the internet with communications tools that are extraordinarily flexible.

Robust Suite of Features for Increased Productivity

Companies are switching to voip more than ever because it offers a robust suite of features that greatly help to improve productivity. Enterprise businesses enjoy call forwarding, call waiting, call routing, call recording, video and voice conferencing, and voicemail. Phone numbers and extensions are managed by team members and managers through one user-friendly platform. This provides better communications, improves collaboration, and offers better customer experience, at a lower operating cost.

Simple to Relocate, Setup, and Manage – Businesses using voip enjoy the ease of setup and worry-free maintenance. These systems require no special technical expertise to setup and manage. Also, there’s little to no maintenance as it’s done automatically, off-site, in the cloud.

Access and Manage All Communications through One Platform – Companies can access and manage texts, email, faxes, voicemail, instant messages, and chat sessions through one simple to use platform. Businesses enjoy streamlined productivity, and this improves revenue streams, which provides a competitive edge with TieTechnology's Enterprise VoIP Phone Systems.

http://www.TieTechnology.com phone services are now available in the following geographical areas:

Alaska, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah, Vermont, Washington, Washington DC, West Virginia, Wisconsin, and Wyoming.

With rapid expansions that are exploding in the following southeastern states and cities

Alabama;
Montgomery, Alabama; Mobile, Alabama; Huntsville, Alabama; Tuscaloosa, Alabama

Kentucky;
Bowling Green, Kentucky; Clarksville, Kentucky; Louisville, Kentucky; Owensboro, Kentucky

South Carolina;
Greenville, South Carolina; Columbia, South Carolina; Charleston, South Carolina;
Myrtle Beach, South Carolina

Virginia;
Washington, Virginia title Washington, Virginia; Virginia Beach, Virginia; Richmond, Virginia; Roanoke, Virginia

About TieTechnology LLC
TieTechnology specializes in small business service based solutions for businesses. Services provided by TieTechnology LLC, include: unified communications, merchant credit card processing, merchant cash advances and online marketing strategies. The advantages of doing business with TieTechnology is their commitment to customer service excellence and their offering of one stop solutions to all business to business service product needs for the customers’ convenience.

About Lower Internet Cost Services
http://lowerinternetcost.com services is the internet services division of TieTechnology LLC. Through LowerInternetCost.com, the company provides affordable and high quality real time services for business users who want reliable businesses fixed wireless, business T1, business Ethernet and business phone equipment services. Since 2002, this department has had a brilliant track record of meeting client expectations and delivering the best solutions to clients based on their budget and requirements.

About Business Cash Advance Services
http://www.BusinessCashAdvanceGuru.com is a division authorized by TieTechnology, LLC. Business Cash Advance Guru’s merchant cash advance division specializes in helping small business owners realize their dreams. That’s why we created our merchant cash advance program in 2003, and continue to be a merchant cash advance leader in the industry, offering the most flexible payment options and the lowest interest rates and in the business.

About TieTechnology VoIP Business Phone Services
VoIP Business Phone Services is the unified communications division of TieTechnology, LLC. that provides the highest quality telecommunications and engineering consulting services within the telecommunications industry at the most competitive rates. Businesses need high speed internet and reliable phone connections to stay ahead of their competitors and fulfill all client expectations. Companies that operate internationally need robust phone and internet systems like business voip business satellite, p2p (point to point), VPN (virtual private network) and much more. The mission of TieTechnology VoIP Business Phone Services’ is to provide affordable and high quality services for business users who want reliable business fixed wireless, business Ethernet, and business phone services.

Further information about the best VoIP phone systems and features for your business, look at:
http://www.TieTechnology.com or http://www.LowerInternetcost.com

The telecommunications engineering and consulting services can be
accessed online at: http://www.voip-businessphoneservices.com.

Don Anderson
TieTechnology VoIP Business Phone Services
(813) 856-0328
email us here

TieTechnology Phone Service Yealink Tutorial


Source: EIN Presswire

Inhaler Group UK explore the impact of inhaled therapies next March in London

SMi’s 13th annual Asthma & COPD conference returns to London on the 29th and 30th March 2017

It is of utmost importance for industry to collaborate to ensure that respiratory medicines are used safely by patients and that adherence to treatment is addressed.

— SMi Group

LONDON, UNITED KINGDOM, December 13, 2016 /EINPresswire.com/ — Monica Fletcher OBE, Chief Executive of Education for Health and Chair of the UK Inhaler Group joins this year’s speaker panel for Asthma & COPD 2017. Monica will be speaking on day one of the conference on ‘Maximising the use and impact of inhaled therapies; addressing the true needs of patients and HCPs’, where she will discuss crucial matters surrounding inhalers, such as patient compliance and educating patient and healthcare professionals. She will explore:

• How do patients and HCPs describe their inhalers?
• Will technology help or hinder adherence?
• How can we educate patients and HCPs?

Last year AstraZeneca changed the blue colour of their Duaklir® Genuair® inhaler over concerns about patients mistakenly using this as a reliever inhaler. ‘’The UKIG recommend that blue colouring on inhaler devices should be reserved for “reliever” inhalers and should not be present on “preventer” inhalers, in case this confuses patients who may mistakenly take extra doses during the day or night rather than using their “reliever” inhaler." *(Source)
Monica praised this change from AstraZeneca; "We are delighted with the proactive response from AstraZeneca to collective concerns about the importance of colour coding inhaler devices and the potential for serious patient safety risks associated with the colour of inhaler devices. By changing the colour of the Duaklir® Genuair® inhaler we believe that greater clarity and patient safety will result.” *(Source)

It is of utmost importance for industry to collaborate to ensure that respiratory medicines are used safely by patients and that adherence to treatment is addressed. Therefore it highlights the need to address so many ongoing issues regarding these two respiratory diseases.

Other sessions which are not to be missed include insightful presentations from: MHRA, GSK, Boehringer Ingelheim, Glenmark Pharmaceuticals, Janssen, Novartis, Teva, AstraZeneca, MedImmune, Mylan, Imperial College of London, Actavis and many more…

Hot topics for the 2017 agenda include: regulatory updates, therapeutic developments, COPD updates, novel approaches to treatment and electronic health monitoring.

Two CPD certified pre-conference workshops will be hosted alongside the conference by Cambridge Consultants and Janssen.

There is currently an early bird offer available; book by 16th of December to save £200 off the conference price. Register at www.asthma-copd.co.uk/EIN

For sponsorship packages: Contact Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk

For delegate enquiries: Contact Ameenah Begum on +44 (0)20 7827 6166 or email abegum@smi-online.co.uk

For media enquiries, contact Zoe Gale on +44 20 7827 6138 or zgale@smi-online.co.uk

13th annual Asthma & COPD
29-30 March 2017
London, UK
www.asthma-copd.co.uk/EIN
Contact e-mail: zgale@smi-online.co.uk
Contact tel: +44 (0) 207 827 6166
#asthmacopdsmi
*(Source) http://bit.ly/2gpt6ZF

—- END —-
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Zoe Gale
SMi Group
02078276132
email us here


Source: EIN Presswire

Lipodystrophy Therapeutic and Drug Pipeline Review H2


Wise.Guy12

Wise.Guy.

Lipodystrophy Therapeutic Pipeline Market Review, H2 2016

PUNE, INDIA, December 14, 2016 /EINPresswire.com/ — GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/649790-lipodystrophy-pipeline-review-h2-2016

The report provides comprehensive information on the therapeutics under development for Lipodystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lipodystrophy and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
– The report provides a snapshot of the global therapeutic landscape of Lipodystrophy
– The report reviews pipeline therapeutics for Lipodystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Lipodystrophy therapeutics and enlists all their major and minor projects
– The report assesses Lipodystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Lipodystrophy

Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand important and diverse types of therapeutics under development for Lipodystrophy
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Lipodystrophy pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Content
Lipodystrophy Overview 6
Therapeutics Development 7
Pipeline Products for Lipodystrophy – Overview 7
Lipodystrophy – Therapeutics under Development by Companies 8
Lipodystrophy – Pipeline Products Glance 9
Late Stage Products 9
Early Stage Products 10
Lipodystrophy – Products under Development by Companies 11
Lipodystrophy – Companies Involved in Therapeutics Development 12
Aegerion Pharmaceuticals, Inc. 12
Akcea Therapeutics Inc 13
Ambrx, Inc. 14
Amunix Operating Inc. 15
Bolder Biotechnology, Inc. 16
Lipodystrophy – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 23
Drug Profiles 25
AMX-342 – Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
ARX-328 – Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
BBT-031 – Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
metreleptin – Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
volanesorsen sodium – Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Continued…

ACCESS REPORT @ https://www.wiseguyreports.com/reports/649790-lipodystrophy-pipeline-review-h2-2016

Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Osteoporosis: Drug, Therapeutics and Forecast 2016 – 2021


Wise.Guy12

Wise.Guy.

Osteoporosis Global Market 2016 Analysis and Forecast to 2021

PUNE, INDIA, December 14, 2016 /EINPresswire.com/ — GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/598296-osteoporosis-therapeutics-in-asia-of-anabolic-therapies

Osteoporosis Therapeutics in Asia-Pacific Markets to 2022 – Growth Driven by Rising Prevalence, Growing Awareness and Expected Launch of Anabolic Therapies

Summary
Osteoporosis, the most common metabolic bone disease, is characterized by low bone mass, microarchitectural deterioration of bone tissue, and a consequent increase in fracture risk. Osteoporosis is generally known as an asymptomatic disease, as there are no visible signs until a fracture occur. In most of the cases, fracture is the clinical outcome associated with osteoporosis, and it has a complex pathogenesis that involves trauma to the bone and increased skeletal fragility. Osteoporosis is a major global public health problem, associated with significant morbidity, mortality, and socioeconomic burden. An aging global population will result in an increased number of people living with the condition, thereby acting as a driver for revenue growth.

The osteoporosis market is undergoing a gradual transition from a focus on antiresorptive therapies to anabolic drug treatment. The market is set to be driven by recently launched products, and the approval of drugs that will supplement current market leaders and offer greater therapeutic options. The marketed products landscape comprises a wide range of treatment options, including bisphosphonates, SERMs, RANKL inhibitors, a dual-action non-bisphosphonate (strontium ranelate), calcitonins and PTH analogues. Nevertheless, significant unmet need remains for products that can improve bone formation, as well as effective antiresorptive therapies that offer increased compliance with few side effects.

Scope
The osteoporosis Asia-Pacific market will be valued at $7.7 billion in 2022, growing from $4.5 billion in 2015 at a CAGR of 7.8%.
– Bisphosphonates and SERMs dominate the osteoporosis market. However, unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs of the osteoporosis market?
– How will immunotherapies such as Prolia contribute to growth?
– What effect will the patent expirations of currently branded therapies have on market value?
The pipeline contains a range of molecule types and molecular targets, including those that are well established in osteoporosis, and novel, first-in-class therapies.
– Which molecular targets appear most frequently in the pipeline?
– Is there strong potential for the pipeline to address unmet needs within the osteoporosis market?
– Will the pipeline address unmet needs related to limited anabolic therapies for osteoporosis patients?
The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value, due to the emergence of novel therapies.
– How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
– How could changes in risk factors such as aging population, calcium and vitamin D deficiency influence the market?
Various drivers and barriers will influence the market over the forecast period.
– What are the barriers that limit the uptake of premium-priced therapeutics in the assessed countries?
– Which factors are most likely to drive the market in these countries?

Reasons to buy
This report will allow you to –
– Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
– Visualize the composition of the osteoporosis market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
– Analyze the osteoporosis pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
– Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, – and how they will compete with other therapies.
– Predict osteoporosis market growth in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as individual contributions of promising late-stage molecules to market growth.
– Identify commercial opportunities in the osteoporosis deals landscape by analyzing trends in licensing and co-development deals.

Table of Contents
1 Table of Contents 5
2 Introduction 10
3 Marketed Products 26
4 Pipeline Analysis 42
5 Clinical Trial Analysis 61
6 Multi-Scenario Forecast 73
7 Drivers and Barriers 92
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/598296-osteoporosis-therapeutics-in-asia-of-anabolic-therapies

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Medical Robotic Systems Market 2016 Global Trends, Market Share, Industry Size, Growth, Opportunities & Forecast to 2021

Global Medical Robotic Systems Market 2016 Share, Trend, Segmentation and Forecast to 2021

PUNE, INDIA, December 14, 2016 /EINPresswire.com/ — Description

The report “Global Medical Robotic Systems Market – Focus on Orthopedic Robotic Surgery Market Outlook 2021” provides an in-depth analysis of global medical robotic systems market and robotic surgery market with focus on orthopedics segment. The industry has worldwide been acknowledged as a technological field with major breakthrough expected in upcoming years.
Growth of the industry is attributed to use of robotic surgery for treatment of various chronic diseases such as arthritis, cancer, respiratory diseases and cardiovascular diseases. These diseases are more prevalent in ageing population. Hence growing incidence of chronic diseases, ageing population, high precision rate associated with surgical robots and rise in demand of robotic surgery in emerging markets are seen as major growth drivers of the industry. However, factors such as high regulatory risk, medical device recalls, lack of trained workforce and high-entry level costs are major restraints.

Request a sample report @ https://www.wiseguyreports.com/sample-request/817495-global-medical-robotic-systems-market-outlook-2021

Global Medical Robotics market is dominated by Intutive Surgical Inc., Stryker Corporation, Accuray Inc., Hansen Medical, Inc., among others. Intutive Surgical Inc., Stryker Corporation and Accuray Inc. are profiled herein based on attributes such as business overview, product segments, financial and business strategies.
The report “Global Medical Robotic Systems Market – Focus on Orthopedic Robotic Surgery Market Outlook 2021” provides an in-depth analysis of global medical robotic systems market and robotic surgery market with focus on orthopedics segment. The industry has worldwide been acknowledged as a technological field with major breakthrough expected in upcoming years.

Growth of the industry is attributed to use of robotic surgery for treatment of various chronic diseases such as arthritis, cancer, respiratory diseases and cardiovascular diseases. These diseases are more prevalent in ageing population. Hence growing incidence of chronic diseases, ageing population, high precision rate associated with surgical robots and rise in demand of robotic surgery in emerging markets are seen as major growth drivers of the industry. However, factors such as high regulatory risk, medical device recalls, lack of trained workforce and high-entry level costs are major restraints.

Global Medical Robotics market is dominated by Intutive Surgical Inc., Stryker Corporation, Accuray Inc., Hansen Medical, Inc., among others. Intutive Surgical Inc., Stryker Corporation and Accuray Inc. are profiled herein based on attributes such as business overview, product segments, financial and business strategies.

Complete report details @ https://www.wiseguyreports.com/reports/817495-global-medical-robotic-systems-market-outlook-2021

Table Of Contents

1. Executive Summary

2. Research Methodology

3. Medical Robotic Systems
3.1 Medical Robotics: Overview
3.1.1 Introduction
3.1.2 Classification
3.1.3 Applications
3.2 Medical Robotic Systems Market Analysis
3.2.1 Market Sizing (Actual & Forecasted)
3.2.2 Market Share by Segments (Actual & Forecasted)
3.2.3 Market Share by Region

4. Robotic Surgery
4.1 Robotic Surgery: Overview
4.1.1 Introduction
4.1.2 Classification
4.1.3 Advantages & Disadvantages
4.1.4 Applications
4.2 Robotic Surgery Market Analysis
4.2.1 Market Sizing Actual & Forecasted
4.2.2 The US Robotic Surgery Market

5. Orthopedic Robotics Surgery Market
5.1 Introduction
5.2 Market Analysis
5.2.1 Market Sizing (Actual & Forecasted)
5.3 The US Market
5.3.1 Market Sizing (Actual & Forecasted)
5.3.2 Market Penetration

6. da Vinci Surgical Systems
6.1 Introduction
6.2 Market Analysis
6.2.1 Market Sizing
6.2.2 Market Share by Nations
6.3 Procedure Trend
6.3.1 Procedures by Type
6.3.2 da Vinci’s Prostatectomy
6.3.3 da Vinci’s Hysterectomy

7. Market Dynamics
7.1 Growth Drivers
7.1.1 Increasing Prevalence of Chronic Diseases
7.1.2 Growing Geriatric Population
7.1.3 High Precision Rate
7.1.4 Demand in Emerging Markets
7.2 Challenges
7.2.1 Regulatory Risk
7.2.2 Medical Device Recalls
7.2.3 Lack of Trained Workforce
7.2.4 High-Entry Level Cost
7.3 Industry Trends & Developments
7.3.1 Emerging Robotic Surgery Platforms
7.3.2 Collaborations in the Industry
7.3.3 Surgical Nanorobots

8. Competitive Landscape

Get It Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=817495

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire